SRR1435484
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.445
- PANCREAS_BETA_CELLS+0.318
- HEDGEHOG_SIGNALING+0.284
- SPERMATOGENESIS+0.261
- ANGIOGENESIS+0.199
- UV_RESPONSE_DN+0.179
- ESTROGEN_RESPONSE_LATE+0.147
- APICAL_SURFACE+0.134
- ESTROGEN_RESPONSE_EARLY+0.110
- XENOBIOTIC_METABOLISM+0.075
Top 10 suppressed
- MYC_TARGETS_V1-0.602
- INTERFERON_ALPHA_RESPONSE-0.570
- E2F_TARGETS-0.512
- MTORC1_SIGNALING-0.470
- INTERFERON_GAMMA_RESPONSE-0.453
- MYC_TARGETS_V2-0.450
- CHOLESTEROL_HOMEOSTASIS-0.445
- G2M_CHECKPOINT-0.432
- UNFOLDED_PROTEIN_RESPONSE-0.427
- DNA_REPAIR-0.412
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1418127 | GTEX | — | 0.965 |
| 2 | SRR1388378 | GTEX | — | 0.963 |
| 3 | SRR1500868 | GTEX | — | 0.955 |
| 4 | BS_C7N3J4NW | high-grade glioma | — | 0.955 |
| 5 | SRR1375976 | GTEX | — | 0.953 |
| 6 | SRR1444678 | GTEX | — | 0.951 |
| 7 | SRR1323043 | GTEX | — | 0.949 |
| 8 | SRR1331751 | GTEX | — | 0.949 |
| 9 | BS_SM8VQFPD | DNET | — | 0.947 |
| 10 | SRR1477080 | GTEX | — | 0.947 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.445 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.318 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.284 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.261 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.199 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.179 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.147 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.134 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.075 | Inavolisib | — uncovered |
| MYOGENESIS | 0.045 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.029 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.023 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.014 | Inavolisib | — uncovered |